PC-SPES: Herbal formulation for prostate cancer

Leonard S. Marks, Robert S. DiPaola, Peter Nelson, Sophie Chen, David Heber, Arie S. Belldegrun, Franklin C. Lowe, John Fan, Floyd E. Leaders, Allan J. Pantuck, Varro E. Tyler

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

PC-SPES is a potent eight-herb formulation sold directly to consumers; it has promising efficacy in the treatment of prostate cancer (CaP). The product induces a castrate status in most, if not all, men, resulting in a 50% or greater prostate-specific antigen reduction in the great majority of men with androgen-dependent CaP and in more than one half of the men with androgen-independent CaP. The duration of response is not yet clear. The efficacy of PC-SPES appears to exceed that of androgen ablation alone, but is not necessarily separate from an estrogenic effect. Common side effects include gynecomastia, nipple tenderness, loss of libido, and impotency; uncommon side effects include a 4% incidence of thromboembolic phenomena, but also two reports of bleeding diatheses. The mechanisms of action may involve downregulation of the androgen receptor, induction of apoptosis by way of inhibition of the bcl-2 gene, and increased expression of p53. Two marker compounds in PC-SPES are baicalin and oridonin, both of which exhibit antiproliferative effects in CaP cell lines. Thousands of men are currently obtaining this nonprescription medicine, and physicians should ask patients specifically about its use. PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalUrology
Volume60
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Androgens
Gynecomastia
bcl-2 Genes
Libido
Nipples
Disease Susceptibility
Androgen Receptors
Prostate-Specific Antigen
Estrogens
Down-Regulation
Medicine
herbal preparation PC-SPES
Apoptosis
Hemorrhage
Physicians
Gene Expression
Cell Line
Incidence

ASJC Scopus subject areas

  • Urology

Cite this

Marks, L. S., DiPaola, R. S., Nelson, P., Chen, S., Heber, D., Belldegrun, A. S., ... Tyler, V. E. (2002). PC-SPES: Herbal formulation for prostate cancer. Urology, 60(3), 369-375. https://doi.org/10.1016/S0090-4295(02)01913-1

PC-SPES : Herbal formulation for prostate cancer. / Marks, Leonard S.; DiPaola, Robert S.; Nelson, Peter; Chen, Sophie; Heber, David; Belldegrun, Arie S.; Lowe, Franklin C.; Fan, John; Leaders, Floyd E.; Pantuck, Allan J.; Tyler, Varro E.

In: Urology, Vol. 60, No. 3, 2002, p. 369-375.

Research output: Contribution to journalArticle

Marks, LS, DiPaola, RS, Nelson, P, Chen, S, Heber, D, Belldegrun, AS, Lowe, FC, Fan, J, Leaders, FE, Pantuck, AJ & Tyler, VE 2002, 'PC-SPES: Herbal formulation for prostate cancer', Urology, vol. 60, no. 3, pp. 369-375. https://doi.org/10.1016/S0090-4295(02)01913-1
Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS et al. PC-SPES: Herbal formulation for prostate cancer. Urology. 2002;60(3):369-375. https://doi.org/10.1016/S0090-4295(02)01913-1
Marks, Leonard S. ; DiPaola, Robert S. ; Nelson, Peter ; Chen, Sophie ; Heber, David ; Belldegrun, Arie S. ; Lowe, Franklin C. ; Fan, John ; Leaders, Floyd E. ; Pantuck, Allan J. ; Tyler, Varro E. / PC-SPES : Herbal formulation for prostate cancer. In: Urology. 2002 ; Vol. 60, No. 3. pp. 369-375.
@article{46cf9b08b0dc47eb86188745be955caa,
title = "PC-SPES: Herbal formulation for prostate cancer",
abstract = "PC-SPES is a potent eight-herb formulation sold directly to consumers; it has promising efficacy in the treatment of prostate cancer (CaP). The product induces a castrate status in most, if not all, men, resulting in a 50{\%} or greater prostate-specific antigen reduction in the great majority of men with androgen-dependent CaP and in more than one half of the men with androgen-independent CaP. The duration of response is not yet clear. The efficacy of PC-SPES appears to exceed that of androgen ablation alone, but is not necessarily separate from an estrogenic effect. Common side effects include gynecomastia, nipple tenderness, loss of libido, and impotency; uncommon side effects include a 4{\%} incidence of thromboembolic phenomena, but also two reports of bleeding diatheses. The mechanisms of action may involve downregulation of the androgen receptor, induction of apoptosis by way of inhibition of the bcl-2 gene, and increased expression of p53. Two marker compounds in PC-SPES are baicalin and oridonin, both of which exhibit antiproliferative effects in CaP cell lines. Thousands of men are currently obtaining this nonprescription medicine, and physicians should ask patients specifically about its use. PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed.",
author = "Marks, {Leonard S.} and DiPaola, {Robert S.} and Peter Nelson and Sophie Chen and David Heber and Belldegrun, {Arie S.} and Lowe, {Franklin C.} and John Fan and Leaders, {Floyd E.} and Pantuck, {Allan J.} and Tyler, {Varro E.}",
year = "2002",
doi = "10.1016/S0090-4295(02)01913-1",
language = "English (US)",
volume = "60",
pages = "369--375",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - PC-SPES

T2 - Herbal formulation for prostate cancer

AU - Marks, Leonard S.

AU - DiPaola, Robert S.

AU - Nelson, Peter

AU - Chen, Sophie

AU - Heber, David

AU - Belldegrun, Arie S.

AU - Lowe, Franklin C.

AU - Fan, John

AU - Leaders, Floyd E.

AU - Pantuck, Allan J.

AU - Tyler, Varro E.

PY - 2002

Y1 - 2002

N2 - PC-SPES is a potent eight-herb formulation sold directly to consumers; it has promising efficacy in the treatment of prostate cancer (CaP). The product induces a castrate status in most, if not all, men, resulting in a 50% or greater prostate-specific antigen reduction in the great majority of men with androgen-dependent CaP and in more than one half of the men with androgen-independent CaP. The duration of response is not yet clear. The efficacy of PC-SPES appears to exceed that of androgen ablation alone, but is not necessarily separate from an estrogenic effect. Common side effects include gynecomastia, nipple tenderness, loss of libido, and impotency; uncommon side effects include a 4% incidence of thromboembolic phenomena, but also two reports of bleeding diatheses. The mechanisms of action may involve downregulation of the androgen receptor, induction of apoptosis by way of inhibition of the bcl-2 gene, and increased expression of p53. Two marker compounds in PC-SPES are baicalin and oridonin, both of which exhibit antiproliferative effects in CaP cell lines. Thousands of men are currently obtaining this nonprescription medicine, and physicians should ask patients specifically about its use. PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed.

AB - PC-SPES is a potent eight-herb formulation sold directly to consumers; it has promising efficacy in the treatment of prostate cancer (CaP). The product induces a castrate status in most, if not all, men, resulting in a 50% or greater prostate-specific antigen reduction in the great majority of men with androgen-dependent CaP and in more than one half of the men with androgen-independent CaP. The duration of response is not yet clear. The efficacy of PC-SPES appears to exceed that of androgen ablation alone, but is not necessarily separate from an estrogenic effect. Common side effects include gynecomastia, nipple tenderness, loss of libido, and impotency; uncommon side effects include a 4% incidence of thromboembolic phenomena, but also two reports of bleeding diatheses. The mechanisms of action may involve downregulation of the androgen receptor, induction of apoptosis by way of inhibition of the bcl-2 gene, and increased expression of p53. Two marker compounds in PC-SPES are baicalin and oridonin, both of which exhibit antiproliferative effects in CaP cell lines. Thousands of men are currently obtaining this nonprescription medicine, and physicians should ask patients specifically about its use. PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed.

UR - http://www.scopus.com/inward/record.url?scp=0036753749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036753749&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)01913-1

DO - 10.1016/S0090-4295(02)01913-1

M3 - Article

C2 - 12350462

AN - SCOPUS:0036753749

VL - 60

SP - 369

EP - 375

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -